Citigroup initiated coverage on Veradermics with a new price target
$MANE
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of Veradermics with a rating of Buy and set a new price target of $85.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/15/2026 | $170.00 | Buy | B. Riley Securities |
| 6/2/2026 | $136.00 | Buy | Needham |
| 3/2/2026 | Overweight | Cantor Fitzgerald | |
| 3/2/2026 | $85.00 | Buy | Citigroup |
| 3/2/2026 | $75.00 | Buy | Jefferies |
| 3/2/2026 | $75.00 | Outperform | Leerink Partners |
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, a proprietary extended-release oral min
VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0% (twice-daily dosing) of patients reporting ‘improved’ or ‘much improved’ outcomes at Month 6 Robust hair growth was observed with a mean increase in non-vellus target area hair count (TAHC) of 22.7 hairs/cm² and 23.3 hairs/cm² at Month 6, in once and twice daily dosing regimens, respectively VDPHL01 demonstrated a favorable safety and tolerability profile in females that was generally consistent with
Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss. Webcast Details: Time: Wednesday, July 15, 2026 at 8:00 a.m. ET. Joining: The event and the accompanying slides will be availab
4/A - Veradermics, Inc (0001827635) (Issuer)
4 - Veradermics, Inc (0001827635) (Issuer)
4 - Veradermics, Inc (0001827635) (Issuer)
8-K - Veradermics, Inc (0001827635) (Filer)
SCHEDULE 13G/A - Veradermics, Inc (0001827635) (Subject)
D - Veradermics, Inc (0001827635) (Filer)
4 - Veradermics, Inc (0001827635) (Issuer)
3 - Veradermics, Inc (0001827635) (Issuer)
4/A - Veradermics, Inc (0001827635) (Issuer)
B. Riley Securities initiated coverage of Veradermics with a rating of Buy and set a new price target of $170.00
Needham initiated coverage of Veradermics with a rating of Buy and set a new price target of $136.00
Cantor Fitzgerald initiated coverage of Veradermics with a rating of Overweight
VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0% (twice-daily dosing) of patients reporting ‘improved’ or ‘much improved’ outcomes at Month 6 Robust hair growth was observed with a mean increase in non-vellus target area hair count (TAHC) of 22.7 hairs/cm² and 23.3 hairs/cm² at Month 6, in once and twice daily dosing regimens, respectively VDPHL01 demonstrated a favorable safety and tolerability profile in females that was generally consistent with
Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss. Webcast Details: Time: Wednesday, July 15, 2026 at 8:00 a.m. ET. Joining: The event and the accompanying slides will be availab
VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 Rapid and robust hair growth was achieved with VDPHL01 treatment as demonstrated by a mean increase in non-vellus target area hair count (TAHC) of 30.3 hairs/cm² (once daily dosing; p<0.0001) and 33.0 hairs/cm² (twice daily dosing; p<0.0001) versus 7.3 hairs/cm² for placebo at Month 6 Approximately 79.3% (QD) and 86.0% (BID) of patients reported any improvement in patient-reported outcomes (PRO) versus 35.6% of placebo patient